WCCT Global Chosen as Strategic Partner for Vaccine Development

COSTA MESA, Calif., January 22, 2015/PRNewswire-iReach/—WCCT Global, a full service contract research organization was announced today to be a strategic partner with Dynport Vaccine Company along with two other CROs for supporting clinical trials to evaluate Anti-Infective Drugs with the NIAID. This partnership is publicized just shortly after the strategic collaboration that was reached between WCCT Global and the NIAID for influenza challenge research. This agreement between DynPort and WCCT Global will be directed toward phase I support to demonstrate the safety of investigational therapeutic products being studied by the NIAID in order to provide data for appropriate human dosing in later phase development. The types of therapeutic agents that will be investigated include potential medications against bacterial, parasitic, and fungal pathogens.

WCCT Global’s CEO Dr. Kenneth Kim stated, “WCCT Global was chosen as a strategic partner  because of our influenza challenge capabilities and our excellent track record in the successful execution of phase I studies for anti-infective agents. We look forward to working with DynPort and the other partners in this exciting research venture.”

More about WCCT Global:

WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.